Per Norlén, Evaxion Biotech CEO

Evax­ion teas­es 67% re­sponse rate in PhI metasta­t­ic melanoma tri­al

Evax­ion Biotech said eight of 12 pa­tients with metasta­t­ic melanoma who re­ceived a com­bi­na­tion of the lead can­di­date and an un­named check­point in­hibitor had a pos­i­tive re­sponse in a Phase I tri­al, in a sneak peak of clin­i­cal da­ta set to be pre­sent­ed at AS­CO next week.

The Dan­ish biotech is de­vel­op­ing EVX-01, a per­son­al­ized can­cer im­munother­a­py that builds off its AI plat­form, which iden­ti­fies neoanti­gens for each pa­tient.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.